Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€173.70

€173.70

-0.110%
-0.2
-0.110%
€180.90

€180.90

 
18.09.24 / Tradegate WKN: A1J84E / Symbol: ABBV / Name: AbbVie / Stock / Pharmaceuticals / Large Cap /
Latest predictions
€186.74
23.08.24
-1.36%
buy
€199.34
12.08.24
0.38%
buy
€182.54
05.08.24
3.38%
buy
€185.50
28.07.24
1.82%
buy
€184.08
26.07.24
1.20%
buy
€193.31
26.07.24
3.60%
buy
Best running prediction
€166.50
01.12.23
34.38%
buy
Your prediction

AbbVie Inc. Stock

The price for the AbbVie Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.200 (-0.110%).
With 34 Buy predictions and not a single Sell prediction AbbVie Inc. is an absolute favorite of our community.
With a target price of 180 € there is a slightly positive potential of 3.63% for AbbVie Inc. compared to the current price of 173.7 €.
Our community identified positive and negative aspects for AbbVie Inc. stock for the coming years. 1 users see the criterium "Expected dividend yield" as a plus for the AbbVie Inc. stock. On the other hand our users think that "Debt" could be a problem in the future.

AbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.

Pros and Cons of AbbVie Inc. in the next few years

Pros
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of AbbVie Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
AbbVie Inc. -0.110% -3.684% -1.012% 22.004% 24.268% 89.548% 167.846%
Johnson & Johnson -0.390% -0.948% 3.997% -0.661% 6.215% 7.107% 28.415%
Elanco Animal Health Inc. -1.330% -0.850% -1.597% 15.986% -3.402% -52.733% -
Biogen Inc. -0.170% -2.006% -2.622% -25.397% -24.385% -30.311% -17.339%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

Analyzing the financials of AbbVie (ABBV) reveals a company that exhibits both promising strengths and notable challenges. The pharmaceutical giant has managed to sustain significant revenue levels and maintain a relatively solid position within the industry. However, certain metrics highlight potential concerns regarding profitability and debt that merit careful consideration.

Robust Revenue Generation: AbbVie reported total revenue reaching approximately $54.99 billion over the last twelve months (TTM). This impressive figure underscores the company's ability to generate consistent sales, primarily driven by its product portfolio, notably immunology and oncology drugs.

Substantial EBITDA Margin: The EBITDA stands at around $26.25 billion, indicating a solid operational performance in generating earnings before interest, taxes, depreciation, and amortization. With an EBITDA margin of about 47.7%, AbbVie showcases its competent operational efficiency, allowing it to retain a significant portion of its revenue as earnings.

Comments

Prediction Buy
Perf. (%) -1.36%
Target price 186.742
Change
Ends at 23.08.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Piper Sandler from $196.00 to $209.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 0.38%
Target price 199.339
Change
Ends at 12.08.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Morgan Stanley from $211.00 to $218.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 3.38%
Target price 182.540
Change
Ends at 05.08.25

AbbVie Inc. (NYSE: ABBV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $200.00 price target on the stock.
Ratings data for ABBV provided by MarketBeat
Show more

News

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management
Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

-          Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the

Can AbbVie Regain Its Status As a Top Dividend Growth Stock?: https://g.foolcdn.com/editorial/images/790803/u-turn.jpg
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?

AbbVie (NYSE: ABBV) has long been a darling of dividend growth investors, and for good reason. Since its spinoff from Abbott Laboratories in 2013, the pharmaceutical titan has been a dividend growth

3 Stocks to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/790595/hands-behind-head-young-man.jpg
3 Stocks to Buy and Hold Forever

The conventional wisdom is that there are two important aspects of timing in investing: when to buy a stock and when to sell it. But are there some stocks that allow you to eliminate the selling